316 related articles for article (PubMed ID: 26637771)
61. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Broccoli A; Argnani L; Zinzani PL
Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
[TBL] [Abstract][Full Text] [Related]
62. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.
Chihara D; Pro B; Loghavi S; Miranda RN; Medeiros LJ; Fanale MA; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Neelapu SS; Younes A; Fowler NH; Rodriguez MA; Wang M; Kwak LW; McLaughlin P; Dang NH; Oki Y
Br J Haematol; 2015 Nov; 171(4):509-16. PubMed ID: 26260306
[TBL] [Abstract][Full Text] [Related]
63. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
[TBL] [Abstract][Full Text] [Related]
64. [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
Huang HQ; Peng YL; Lin XB; Sun XF; Lin TY; Xia ZJ; Li YH; Cai QQ; He YJ; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1443-7. PubMed ID: 15566653
[TBL] [Abstract][Full Text] [Related]
65. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
66. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
[TBL] [Abstract][Full Text] [Related]
67. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
Van de Wyngaert Z; Coppo P; Cervera P; Fabiani B; Lemonnier MP; Corre E; Marjanovic Z; Aoudjhane M; Mohty M; Duléry R
Eur J Haematol; 2021 Apr; 106(4):467-472. PubMed ID: 33320379
[TBL] [Abstract][Full Text] [Related]
68. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
69. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
Armitage JO
Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
[TBL] [Abstract][Full Text] [Related]
70. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
71. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
72. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
[TBL] [Abstract][Full Text] [Related]
73. How I treat the peripheral T-cell lymphomas.
Moskowitz AJ; Lunning MA; Horwitz SM
Blood; 2014 Apr; 123(17):2636-44. PubMed ID: 24615779
[TBL] [Abstract][Full Text] [Related]
74. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.
Lowe EJ; Sposto R; Perkins SL; Gross TG; Finlay J; Zwick D; Abromowitch M;
Pediatr Blood Cancer; 2009 Mar; 52(3):335-9. PubMed ID: 18985718
[TBL] [Abstract][Full Text] [Related]
75. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
76. Refractory Hodgkin lymphoma.
von Tresckow B; Engert A
Curr Opin Oncol; 2013 Sep; 25(5):463-9. PubMed ID: 23942291
[TBL] [Abstract][Full Text] [Related]
77. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.
Zhang XM; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Ren H; Fang H; Zhou LQ; Chen B; Qi SN; Liu QF; Lu NN; Liu XF; Yu ZH
Eur J Haematol; 2013 Mar; 90(3):195-201. PubMed ID: 23301725
[TBL] [Abstract][Full Text] [Related]
78. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
79. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
80. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
